A migraine is may seem a nuisance when they happen once in a while, but in some cases migraines can be extreme. The chronic disorder, which about to 36 million Americans are living with is illustrated through an extremely disabling compilation of neurological symptoms. However, Allergan plc Ordinary Shares (NYSE:AGN) wants to make this a thing of the past with its interactive campaign; Frames of Mind.
A migraine is among the top ten disabling brain illnesses according to the World Health Organization. Its attacks result in hours and days of heavy pain, which sometimes can be severe. Some of the notable symptoms include 15 or more headache days per month, which can last up to four hours a day.
Promotion of awareness with the campaign
Allergan’s Frames of Mind campaign is intended to promote awareness of impact to patients’ everyday lives. It will be creating a platform on which victims can present their artwork explaining how the migraine symptoms affect them. Remember these people experience moments of nausea, vomiting, and extreme sensitivity even to the slightest sound.
The artwork from these people will be of high-resolution version, which shall bear their names, location, and contact information. The Chairman of the American Migraine Foundation, Dr. David Dodick notes, “While the symptoms of migraine can occur in a myriad of unique ways, we hope to underscore……….and empower patients to better manage their condition.”
Given the condition is inclined to lifestyle and environmental factors, Dodick says that the collaboration with Allergan will help in unifying the migraine community. They expect to advocate more the need for access to care and appropriate treatment options.
Advancing of the migraine program
Given that Allergan is a leader in the migraine space, its goal is to support the millions of Americans living with the incapacitating consequences of migraine. In addition to putting more emphasizes on research and treatment options, the program will also involve educating the public about this condition. Chief R&D Officer at Allergan, David Nicholson says that their interest is in making a difference in the lives of the migraine victims.
In the meantime, Allergan’s stock closed at $239.11 a fall of $1.01 or 0.42%
